Another scenario proposed by Brantley-Sieders et al. involves the possibility that EphA2 exerts noncanonical tumour-promoting effects via crosstalk with oncogenic signalling pathways, entirely independent of ephrin ligand stimulation [11]. The gene discussed is EPHA2; the disease is neoplasm.